MedTrace Logo

AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis

NCT01132612 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 275

Last updated 2018-01-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.

Conditions

  • Plaque-type Psoriasis

Interventions

DRUG

AIN457

AIN457A 150 mg powder for solution

DRUG

Placebo

Placebo to AIN457A 150 mg powder for solution

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-11
Primary Completion
2016-10-18
Completion
2016-10-18

Countries

  • United States
  • France
  • Germany
  • Iceland
  • Israel
  • Japan
  • Norway

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01132612 on ClinicalTrials.gov